{site_meta && site_meta.display_name} Logo

InvestorBrandNetwork (IBN)

The latest articles, editorials and news releases from InvestorBrandNetwork (IBN), a growing Investor Brand Platform.

RSS Feed for InvestorBrandNetwork (IBN)

MissionIRNewsBreaks – Forward Industries Inc. (NASDAQ: FWDI) Taps Crypto, Traditional Finance Veteran to Drive Next Phase of Growth

May 13, 2026Forward Industries (NASDAQ: FWDI), focused on building and managing a large-scale Solana (SOL) treasury, recently appointed Mark Brazier as its new CFO. “In his role as CFO, Brazier will oversee Forward’s financial operations, capital structure, financial reporting, capital markets activities, and more, as Forward Industries continues to operate and grow as the worlds-largest publicly traded Solana treasury company,” reads a recent article.


InvestorNewsBreaks – Wearable Devices Ltd. (NASDAQ: WLDS) Unveils Mudra Pro Neural Sensing Platform for AI and XR Innovation

May 13, 2026Wearable Devices (NASDAQ: WLDS) announced the launch of Mudra Pro, a next-generation wearable neural sensing platform designed for developers, researchers, enterprise innovation teams and technology partners building AI, XR and human-machine interaction applications. The wrist-worn platform combines synchronized electromyography, photoplethysmography and inertial measurement sensors with embedded processing, sensor fusion and low-latency Bluetooth communication to support physiological state estimation, intent decoding, behavioral analytics and rapid prototyping, with the company positioning the product as a key outcome of its ai6 Labs initiative focused on AI-native wearable computing and next-generation human-computer interaction.


BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Announces First Patient Dosed in Phase 1b Trial of Sapu003

May 13, 2026Oncotelic Therapeutics (OTCQB: OTLC), alongside Sapu Nano, announced that the first patient has been dosed in the Phase 1b clinical trial evaluating Sapu003, an investigational intravenous Deciparticle(TM) formulation of everolimus for patients with advanced mTOR-sensitive solid tumors. The open-label, dose-escalation study is designed to assess safety, tolerability, pharmacokinetics and preliminary anti-tumor activity across patient cohorts including HR-positive/HER2-negative breast cancer and multiple additional tumor types, with Sapu003 developed as a weekly IV formulation intended to address limitations associated with oral everolimus delivery, including variable absorption and dose-limiting toxicity.


Pentagon Seeks to Mitigate Quantum Computing Risks to the F-35

May 13, 2026The Pentagon is taking steps toshield the F-35’s encryption systems from the growing threat posed by quantum computing. A contract notice published May 6, 2026, by the F-35 Joint Program Office signals the shift to quantum computing-proof encryption.


Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities

May 13, 2026BioMedWire Editorial Coverage: Obesity and type 2 diabetes mellitus (“T2DM”) rank among the most urgent and costly healthcare problems facing the world today, contributing to surging rates of cardiovascular disease, fatty liver disease, kidney complications and ballooning healthcare expenses. What once represented a specialized class of diabetes treatments has grown into one of the most consequential therapeutic categories in modern medicine, with GLP-1 receptor agonists now fundamentally restructuring how obesity, metabolic disease and potentially even neurodegeneration are treated.


Real-Time Intoxication Detection Platforms Target Expanding Multibillion-Dollar Healthcare Opportunities

May 13, 2026BioMedWire Editorial Coverage: For decades, reliably identifying drug and alcohol impairment has been a persistent problem across industries, from traffic enforcement and occupational safety to clinical medicine and public health. Conventional tools such as breathalyzers, blood draws and urine tests are hampered by their intrusiveness, slow turnaround times or inability to capture real-time impairment, especially when multiple substances are involved.


It’s in the Code—the Future of Autonomous Warfare

May 13, 2026AINewsWire Editorial Coverage: The nature of modern conflict is being fundamentally rewritten, driven by the explosive proliferation of cheap, mass-produced drones that are upending the economics of warfare. In war-torn setting such as Ukraine, millions of low-cost systems, often assembled in small workshops or adapted from off-the-shelf commercial hardware, are now performing functions once only sophisticated aircraft and expensive precision munitions could do.